RT Journal Article
SR Electronic
T1 A Novel Formulation of an Ophthalmic Beta-Adrenoceptor Antagonist
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 51
OP 53
VO 46
IS 2
A1 Robert N. Weinreb
A1 Rajni Jani
YR 1992
UL http://journal.pda.org/content/46/2/51.abstract
AB To minimize ocular discomfort while maintaining efficacy, a delivery system for a topical cardioselective β-adrenoceptor antagonist, betaxolol was developed. Betaxolol was formulated at 0.25% concentration in a cationic exchange resin, as a suspension. A polyacrylic acid polymer was added to increase viscosity and to increase residence time in the cul-de-sac. No significant settling was observed throughout a four-week observation period. Thus, resuspension of the formulation by frequent shaking was not required for uniformity. In rabbits, the ocular bioavailability of 0.25% betaxolol suspension was equivalent to that of 0.5% betaxolol solution.